Regeneron Pharmaceuticals, Inc. (REGN)
Surging Earnings Estimates Signal Upside for Regeneron (REGN) Stock
Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
REGN or INCY: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Regeneron (REGN) or Incyte (INCY). But which of these two stocks is more attractive to value investors?
Regeneron (REGN) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Regeneron Pharmaceuticals Q2 Earnings Call Highlights
Regeneron Pharmaceuticals NASDAQ: REGN reported second-quarter revenue growth of 17% from a year earlier to $4.3 billion, supported by continued strength in Dupixent, EYLEA HD and Libtayo. Non-GAAP diluted earnings per share rose 11% to $14.29, while non-GAAP net income reached $1.5 billion.
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2026 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2026 Earnings Call Transcript
Regeneron Q2 Earnings Beat, Sales Up on Dupixent & Eylea HD Strength
REGN's Q2 earnings and revenues beat estimates as robust Eylea HD demand and higher Dupixent profits offset declining Eylea sales.
Regeneron (REGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Regeneron (REGN) Q2 Earnings and Revenues Top Estimates
Regeneron (REGN) came out with quarterly earnings of $14.29 per share, beating the Zacks Consensus Estimate of $10 per share. This compares to earnings of $12.89 per share a year ago.
Will REGN's Q2 Earnings Get a Boost From Dupixent and Eylea HD?
Regeneron's Q2 results could hinge on Dupixent profits and strong Eylea HD, Libtayo sales as investors watch earnings, buybacks and pipeline updates.
Curious about Regeneron (REGN) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Regeneron (REGN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
